Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCD | O00767 | 2/20 | 0.47 |
| ▸ | GRM5 | P41594 | 11/20 | 0.45 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.39 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.39 |
| ▸ | SCD5 | Q86SK9 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | HSD17B13 | Q7Z5P4 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2889894 | 1.00 | SCD (0.47) | SCDGRM5HCRTR1HCRTR2SCD5 | |
| SCHEMBL2897984 | 0.93 | GRM5 (0.55) | SCDGRM5HCRTR1HCRTR2 | |
| SCHEMBL2898403 | 0.93 | GRM5 (0.55) | SCDGRM5HCRTR1HCRTR2 | |
| SCHEMBL2897955 | 0.88 | HCRTR1 (0.40) | SCDGRM5HCRTR1HCRTR2SCD5 | |
| SCHEMBL2897951 | 0.88 | HCRTR1 (0.40) | SCDGRM5HCRTR1HCRTR2SCD5 | |
| SCHEMBL4085913 | 0.86 | SCD (0.42) | SCDGRM5HCRTR1HCRTR2SCD5 | |
| SCHEMBL2890593 | 0.85 | GRM5 (0.46) | GRM5HCRTR1HCRTR2SCD5 | |
| SCHEMBL2890599 | 0.85 | GRM5 (0.46) | GRM5HCRTR1HCRTR2SCD5 | |
| SCHEMBL2893690 | 0.84 | GRM5 (0.55) | GRM5HCRTR1HCRTR2SCD5 | |
| SCHEMBL2893687 | 0.84 | GRM5 (0.55) | GRM5HCRTR1HCRTR2SCD5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7678796-B2 | MGluR5 modulators I | ASTRAZENECA AB (SE) | 2010-03-16 | — | — | US | claimed |
| US-20070259862-A1 | MGluR5 modulators I | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | claimed |
| EP-2672971-A1 | METABOTROPIC GLUTAMATE RECEPTOR GROUP I ANTAGONISTS FOR TREATMENT OF ABNORMAL UNION OF TISSUE | Pharmalundensis AB (SE) | 2013-12-18 | — | — | EP | disclosed |
| WO-2012108831-A1 | METABOTROPIC GLUTAMATE RECEPTOR GROUP I ANTAGONISTS FOR TREATMENT OF ABNORMAL UNION OF TISSUE | REDECO CHEM AB (SE) | 2012-08-16 | — | — | WO | disclosed |
| US-7678796-B2 | MGluR5 modulators I | ASTRAZENECA AB (SE) | 2010-03-16 | — | — | US | disclosed |
| US-20070259862-A1 | MGluR5 modulators I | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259862-A1 | MGluR5 modulators I | GRM5, GRM1, GRIK5 | SCD 1572/4885GRM5 1/4885HCRTR1 191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.